A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 6, 2011, Pages 271-282

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

anti rank ligand; antibody; bone mineral density; bone remodeling; bone turnover; C telopeptide; denosumab; markers; osteoporosis; osteoporotic fractures

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELLULITIS; COLLAGEN SYNTHESIS; DERMATITIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ECZEMA; ERYSIPELAS; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; GLOMERULUS FILTRATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INFECTION RISK; INFLAMMATION; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; NONHUMAN; OSTEOLYSIS; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN INFECTION; TETANY; VERTEBRA FRACTURE;

EID: 84857493658     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11424220     Document Type: Article

References (38)

1. Atfi A. Baron R. (2010) PTH battles TGF-beta in bone. Nat Cell Biol 12: 205–207.
2. Atkins G.J. Rowe P.S. Lim H.P. Welldon K.J. Ormsby R. Wijenayaka A.R. et al. (2011) Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26: 1425–1436.
3. Baron R. Ferrari S. Russell R.G. (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48: 677–692.
4. Bekker P.J. Holloway D. Nakanishi A. Arrighi M. Leese P.T. Dunstan C.R. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348–360.
5. Bekker P.J. Holloway D.L. Rasmussen A.S. Murphy R. Martin S.W. Leese P.T. et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1066.
6. Bilezikian J.P. Matsumoto T. Bellido T. Khosla S. Martin J. Recker R.R. et al. (2009) Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 24: 373–385.
7. Black D.M. Schwartz A.V. Ensrud K.E. Cauley J.A. Levis S. Quandt S.A. et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment – The Fracture Intervention Trial long-term extension (FLEX): A randomized trial. JAMA 296: 2927–2938.
8. Bone H.G. Bolognese M.A. Yuen C.K. Kendler D.L. Miller P.D. Yang Y.C. et al. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96: 972–980.
9. Bone H.G. Bolognese M.A. Yuen C.K. Kendler D.L. Wang H. Liu Y. et al. (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93: 2149–2157.
10. Bonewald L.F. (2011) The amazing osteocyte. J Bone Miner Res 26: 229–238.
11. Boyle W.J. Simonet W.S. Lacey D.L. (2003) Osteoclast differentiation and activation. Nature 423: 337–342.
12. Brown J.P. Prince R.L. Deal C. Recker R.R. Kiel D.P. de Gregorio L.H. et al. (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24: 153–161.
13. Cummings S.R. San Martin J. McClung M.R. Siris E.S. Eastell R. Reid I.R. et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765.
14. Egbuna O.I. Cheung A.M. Siddhanti S. Wang A. Daizadeh N. Anthony M. et al. Treatment of Osteoporosis by RANKL Inhibition with Denosumab in Women at High Cardiovascular Risk and with Renal Impairment Does Not Accelerate Cardiovascular Risk and with Renal Impairment Does Not Accelerate Vascular Calcification. (2010). J Am Soc Nephrol. 21 (10) 640A, Abstract SA-PO2319
15. Eghbali-Fatourechi G. Khosla S. Sanyal A. Boyle W.J. Lacey D.L. Riggs B.L. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221–1230.
16. Eriksen E.F. (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11: 219–227.
17. Hruska K.A. Mathew S. Lund R.J. Memon I. Saab G. (2009) The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol 29: 156–165.
18. Jamal S.A. Ljunggren O. Stehman-Breen C. Cummings S.R. McClung M.R. Goemaere S. et al. (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 1829–1835.
19. Juppner H. (2011) Phosphate and FGF-23. Kidney Int Suppl (121): S24–S27.
20. Kendler D.L. McClung M.R. Freemantle N. Lillestol M. Moffett A.H. Borenstein J. et al. (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22: 1725–1735.
21. Kendler D.L. Roux C. Benhamou C.L. Brown J.P. Lillestol M. Siddhanti S. et al. (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25: 72–81.
22. Lewiecki E.M. Miller P.D. McClung M.R. Cohen S.B. Bolognese M.A. Liu Y. et al. (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22: 1832–1841.
23. Mackie E.J. (2003) Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol 35: 1301–1305.
24. McClung M.R. Lewiecki E.M. Cohen S.B. Bolognese M.A. Woodson G.C. Moffett A.H. et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831.
25. McClung M.R. Lewiecki E.M. Bolognese M. Peacock M. Weimstein R.L. Ding B. Geller M.L. Grauer A. Wagman R.B. Miller P.D. (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover” results of an 8 year phase 2 clinical trial. J Bone Miner Res. supplement 1 (ahead of print).
26. Miller P.D. (2009) Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med 76: 715–723.
27. Miller P.D. Bolognese M.A. Lewiecki E.M. McClung M.R. Ding B.Y. Austin M. et al. (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43: 222–229.
28. Miller P.D. Wagman R.B. Peacock M. Lewiecki E.M. Bolognese M.A. Weinstein R.L. et al. (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96: 394–402.
29. Papapoulos S. Man Z. Mellstrom D. Radominski S. Reginster J-Y Resch H. et al. (2011) Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension. Osteoporosis Internat. 22 (suppl 1), OC25.
30. Price J.S. Sugiyama T. Galea G.L. Meakin L.B. Sunters A. Lanyon L.E. (2011) Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep 9: 76–82.
31. Reid I.R. Miller P.D. Brown J.P. Kendler D.L. Fahrleitner-Pammer A. Valter I. et al. (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25: 2256–2265.
32. Rosen C.J. (2008) Bone remodeling, energy metabolism, and the molecular clock. Cell Metab 7: 7–10.
33. Schwartz A.V. Bauer D.C. Cummings S.R. Cauley J.A. Ensrud K.E. Palermo L. et al. (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25: 976–982.
34. Silverman S.L. (2010) Sclerostin. J Osteoporos 2010: 941419.
35. Stopeck A.T. Lipton A. Body J.J. Steger G.G. Tonkin K. de Boer R.H. et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132–5139.
36. Suda T. Takahashi N. Udagawa N. Jimi E. Gillespie M.T. Martin T.J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345–357.
37. Wang H. Yoshiko Y. Yamamoto R. Minamizaki T. Kozai K. Tanne K. et al. (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23: 939–948.
38. Wypych J. Li M. Guo A. Zhang Z.Q. Martinez T. Allen M.J. et al. (2008) Human IgG 2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283: 16194–16205.